FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007409244> ?p ?o ?g. }

• W2007409244 endingPage "S186" @default.
• W2007409244 startingPage "S186" @default.
• W2007409244 abstract "Purpose/Objective(s)We and others previously identified aldehyde dehydrogenase (ALDH) activity as a marker of pancreatic cancer stem cells (or tumor-initiating cells). The presence of cancer stem cells (CSCs) have been associated with decreased survival and treatment resistance in pancreatic adenocarcinoma. In this study we investigate the role of ALDH expression in predicting survival and patterns of disease recurrence in patients treated with chemoradiation (CRT) following pancreatectomy.Materials/MethodsTissue microarrays using pancreatectomy specimens from 1998 to 2002 at our institution were made, stained for ALDH1, and scored as ALDH-positive or ALDH-negative by two expert pancreatic cancer pathologists blinded to patient outcomes. Physician documentation and radiology reports were used to document patient follow-up information. Time to local failure (TLF), time to distant metastases (TDM), progression-free survival (PFS), and overall survival (OS) were analyzed using SPSS software.ResultsPreviously we found that ALDH expression was associated with worse OS in a cohort of 269 patients with resected pancreatic adenocarcinoma. From this original cohort, adjuvant treatment information was available for 87 patients with ALDH-negative tumors (48.6%) and 41 patients with ALDH-positive tumors (45.6%). In patients treated with adjuvant CRT, median overall survival was superior in the ALDH-negative cohort vs the ALDH-positive cohort, 26.3 months vs 18.2 months (p = 0.011). Further, in patients treated with adjuvant CRT, ALDH-negative patients had statistically greater TLF, TDM, and PFS than their ALDH-positive counterparts (see Table). On multivariate analysis, ALDH positive tumor staining (HR 1.94, p = 0.004) and tumor grade (HR 1.54, p = 0.041) predicted lower OS, and ALDH positive tumor staining (HR 1.83, p = 0.008), tumor grade (HR 1.52, p = 0.038), and tumor size >3 cm (HR 1.65, p = 0.023) predicted decreased PFS.ConclusionsDigital Poster Abstract 1097; TableALDH expression vs survivalALDH negativeALDH positiveP valueAll patientsOS (months)22.4 (n = 87)17.9 (n = 41).119Adjuvant CRTOS (months)26.3 (n = 69)18.2 (n = 35).011PFS (months)18.4 (n = 69)12.3 (n = 35).022TLF (months)45.9 (n = 69)21.0 (n = 35).044TDM (months)27.8 (n = 69)14.8 (n = 35).002 Open table in a new tab Purpose/Objective(s)We and others previously identified aldehyde dehydrogenase (ALDH) activity as a marker of pancreatic cancer stem cells (or tumor-initiating cells). The presence of cancer stem cells (CSCs) have been associated with decreased survival and treatment resistance in pancreatic adenocarcinoma. In this study we investigate the role of ALDH expression in predicting survival and patterns of disease recurrence in patients treated with chemoradiation (CRT) following pancreatectomy. We and others previously identified aldehyde dehydrogenase (ALDH) activity as a marker of pancreatic cancer stem cells (or tumor-initiating cells). The presence of cancer stem cells (CSCs) have been associated with decreased survival and treatment resistance in pancreatic adenocarcinoma. In this study we investigate the role of ALDH expression in predicting survival and patterns of disease recurrence in patients treated with chemoradiation (CRT) following pancreatectomy. Materials/MethodsTissue microarrays using pancreatectomy specimens from 1998 to 2002 at our institution were made, stained for ALDH1, and scored as ALDH-positive or ALDH-negative by two expert pancreatic cancer pathologists blinded to patient outcomes. Physician documentation and radiology reports were used to document patient follow-up information. Time to local failure (TLF), time to distant metastases (TDM), progression-free survival (PFS), and overall survival (OS) were analyzed using SPSS software. Tissue microarrays using pancreatectomy specimens from 1998 to 2002 at our institution were made, stained for ALDH1, and scored as ALDH-positive or ALDH-negative by two expert pancreatic cancer pathologists blinded to patient outcomes. Physician documentation and radiology reports were used to document patient follow-up information. Time to local failure (TLF), time to distant metastases (TDM), progression-free survival (PFS), and overall survival (OS) were analyzed using SPSS software. ResultsPreviously we found that ALDH expression was associated with worse OS in a cohort of 269 patients with resected pancreatic adenocarcinoma. From this original cohort, adjuvant treatment information was available for 87 patients with ALDH-negative tumors (48.6%) and 41 patients with ALDH-positive tumors (45.6%). In patients treated with adjuvant CRT, median overall survival was superior in the ALDH-negative cohort vs the ALDH-positive cohort, 26.3 months vs 18.2 months (p = 0.011). Further, in patients treated with adjuvant CRT, ALDH-negative patients had statistically greater TLF, TDM, and PFS than their ALDH-positive counterparts (see Table). On multivariate analysis, ALDH positive tumor staining (HR 1.94, p = 0.004) and tumor grade (HR 1.54, p = 0.041) predicted lower OS, and ALDH positive tumor staining (HR 1.83, p = 0.008), tumor grade (HR 1.52, p = 0.038), and tumor size >3 cm (HR 1.65, p = 0.023) predicted decreased PFS. Previously we found that ALDH expression was associated with worse OS in a cohort of 269 patients with resected pancreatic adenocarcinoma. From this original cohort, adjuvant treatment information was available for 87 patients with ALDH-negative tumors (48.6%) and 41 patients with ALDH-positive tumors (45.6%). In patients treated with adjuvant CRT, median overall survival was superior in the ALDH-negative cohort vs the ALDH-positive cohort, 26.3 months vs 18.2 months (p = 0.011). Further, in patients treated with adjuvant CRT, ALDH-negative patients had statistically greater TLF, TDM, and PFS than their ALDH-positive counterparts (see Table). On multivariate analysis, ALDH positive tumor staining (HR 1.94, p = 0.004) and tumor grade (HR 1.54, p = 0.041) predicted lower OS, and ALDH positive tumor staining (HR 1.83, p = 0.008), tumor grade (HR 1.52, p = 0.038), and tumor size >3 cm (HR 1.65, p = 0.023) predicted decreased PFS. ConclusionsDigital Poster Abstract 1097; TableALDH expression vs survivalALDH negativeALDH positiveP valueAll patientsOS (months)22.4 (n = 87)17.9 (n = 41).119Adjuvant CRTOS (months)26.3 (n = 69)18.2 (n = 35).011PFS (months)18.4 (n = 69)12.3 (n = 35).022TLF (months)45.9 (n = 69)21.0 (n = 35).044TDM (months)27.8 (n = 69)14.8 (n = 35).002 Open table in a new tab" @default.
• W2007409244 created "2016-06-24" @default.
• W2007409244 creator A5027419360 @default.
• W2007409244 creator A5038721635 @default.
• W2007409244 creator A5048073439 @default.
• W2007409244 creator A5055137078 @default.
• W2007409244 creator A5064975394 @default.
• W2007409244 creator A5070096772 @default.
• W2007409244 creator A5075996646 @default.
• W2007409244 creator A5080450684 @default.
• W2007409244 creator A5082546072 @default.
• W2007409244 creator A5089299130 @default.
• W2007409244 date "2013-10-01" @default.
• W2007409244 modified "2023-10-18" @default.
• W2007409244 title "ALDH-Expressing Cancer Stem Cells Are Associated With Inferior Survival in Patients With Resected Pancreatic Adenocarcinoma Treated With Adjuvant Chemoradiation" @default.
• W2007409244 doi "https://doi.org/10.1016/j.ijrobp.2013.06.479" @default.
• W2007409244 hasPublicationYear "2013" @default.
• W2007409244 type Work @default.
• W2007409244 sameAs 2007409244 @default.
• W2007409244 citedByCount "0" @default.
• W2007409244 crossrefType "journal-article" @default.
• W2007409244 hasAuthorship W2007409244A5027419360 @default.
• W2007409244 hasAuthorship W2007409244A5038721635 @default.
• W2007409244 hasAuthorship W2007409244A5048073439 @default.
• W2007409244 hasAuthorship W2007409244A5055137078 @default.
• W2007409244 hasAuthorship W2007409244A5064975394 @default.
• W2007409244 hasAuthorship W2007409244A5070096772 @default.
• W2007409244 hasAuthorship W2007409244A5075996646 @default.
• W2007409244 hasAuthorship W2007409244A5080450684 @default.
• W2007409244 hasAuthorship W2007409244A5082546072 @default.
• W2007409244 hasAuthorship W2007409244A5089299130 @default.
• W2007409244 hasBestOaLocation W20074092441 @default.
• W2007409244 hasConcept C104317684 @default.
• W2007409244 hasConcept C121608353 @default.
• W2007409244 hasConcept C126322002 @default.
• W2007409244 hasConcept C142724271 @default.
• W2007409244 hasConcept C143998085 @default.
• W2007409244 hasConcept C185592680 @default.
• W2007409244 hasConcept C25747580 @default.
• W2007409244 hasConcept C2780210213 @default.
• W2007409244 hasConcept C2781182431 @default.
• W2007409244 hasConcept C55427017 @default.
• W2007409244 hasConcept C55493867 @default.
• W2007409244 hasConcept C71924100 @default.
• W2007409244 hasConcept C72563966 @default.
• W2007409244 hasConcept C90924648 @default.
• W2007409244 hasConceptScore W2007409244C104317684 @default.
• W2007409244 hasConceptScore W2007409244C121608353 @default.
• W2007409244 hasConceptScore W2007409244C126322002 @default.
• W2007409244 hasConceptScore W2007409244C142724271 @default.
• W2007409244 hasConceptScore W2007409244C143998085 @default.
• W2007409244 hasConceptScore W2007409244C185592680 @default.
• W2007409244 hasConceptScore W2007409244C25747580 @default.
• W2007409244 hasConceptScore W2007409244C2780210213 @default.
• W2007409244 hasConceptScore W2007409244C2781182431 @default.
• W2007409244 hasConceptScore W2007409244C55427017 @default.
• W2007409244 hasConceptScore W2007409244C55493867 @default.
• W2007409244 hasConceptScore W2007409244C71924100 @default.
• W2007409244 hasConceptScore W2007409244C72563966 @default.
• W2007409244 hasConceptScore W2007409244C90924648 @default.
• W2007409244 hasIssue "2" @default.
• W2007409244 hasLocation W20074092441 @default.
• W2007409244 hasOpenAccess W2007409244 @default.
• W2007409244 hasPrimaryLocation W20074092441 @default.
• W2007409244 hasRelatedWork W2007409244 @default.
• W2007409244 hasRelatedWork W2011449731 @default.
• W2007409244 hasRelatedWork W2102245227 @default.
• W2007409244 hasRelatedWork W2127548980 @default.
• W2007409244 hasRelatedWork W2293102240 @default.
• W2007409244 hasRelatedWork W2381201307 @default.
• W2007409244 hasRelatedWork W2566115634 @default.
• W2007409244 hasRelatedWork W4292448967 @default.
• W2007409244 hasRelatedWork W4309566581 @default.
• W2007409244 hasRelatedWork W2593740674 @default.
• W2007409244 hasVolume "87" @default.
• W2007409244 isParatext "false" @default.
• W2007409244 isRetracted "false" @default.
• W2007409244 magId "2007409244" @default.
• W2007409244 workType "article" @default.